Tag

glioblastoma

Paper of the Month
Paper of the month: Improved recovery from post-stroke aphasia with motor cortex electrical stimulation

May 4, 2016

For May 2016 we have selected: Meinzer M, Darkow R, Lindenberg R, Flöel A. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016:139;1152-1163. Language deficits after a stroke can be devastating and have a remarkable impact on the quality of life. Rehabilitation strategies can improve aphasia also in the chronic phases, but there is the overall need of more efficacious and focused treatment strategies. Transcranial direct current stimulation (tDCS) has been shown to change cortical excitability and induce synaptic plasticity without side effects.
Paper of the Month
Paper of the month: Untreated cerebral cavernous malformations and risk of intracranial hemorrhage

March 1, 2016

For March 2016 we have selected: Horne MA, Flemming KD, Su I-C, et al., and the Cerebral Cavernous Malformation Individual Patients Data Meta-analysis Collaborators. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 2016;15:166-173. The incidental finding of cerebral cavernous malformation (CCMs) in brain MRIs is relatively common (1/650 neurologically asymptomatic people, a prevalence second only to cerebral aneurysm).
Paper of the Month
Paper of the month: Efficacy and safety of andexanet to reverse factor Xa inhibitors activity.

February 1, 2016

For February 2016 we have selected: Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;33:2413-2424. There is an increased use of direct factor Xa inhibitors (like apixaban, rivaroxaban, and edoxaban) to prevent stroke in patients with nonvalvular atrial fibrillation since these medications have several advantages compared to vitamin K antagonists.
Top 10 Articles
Top Article: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

September 1, 2012

Abstract: Background: Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically.
Methods: We identified patients… Continue Reading